FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195903332> ?p ?o ?g. }

• W3195903332 abstract "Sodium-glucose-cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control and lowering body weight in patients with type 2 diabetes mellitus. However, the efficacy and safety on weight loss in adults with overweight or obesity but not diabetes remain unclear. In this article, we aimed to identify the efficacy and safety of SGLT2 inhibitors in adults with overweight or obesity but not diabetes in randomized controlled studies (RCTs).We searched for RCTs concerning SGLT2 inhibitors in adults with overweight or obesity but not diabetes in Medline (Ovid SP), Embase (Ovid SP), Cochrane Central Register of Controlled Trials (Ovid SP), and ClinicalTrials.gov up to February 2021. The primary outcomes were changes in body weight and body mass index (BMI). Trial sequential analysis (TSA) was used to test the reliability of the primary outcomes. We analyzed the data using Review Manager 5.3 and pooled data to calculate the mean differences (MDs) or the relative risk (RR). We assessed the evidence quality of evidence of outcomes according to GRADE.Six randomized controlled trials involving 872 individuals were included in the meta-analysis. Compared to the placebo group, the SGLT2 inhibitors group had statistically significant reductions in absolute changes in body weight (MD: -1.42 kg, 95% CI: -1.70 to -1.14; P<0.00001) and BMI (MD: -0.47 kg/m2, 95% CI: -0.63 to -0.31; P<0.00001) in SGLT2 inhibitors group, as indicated by TSA. However, no significant benefits were observed in the SGLT2 inhibitors group in terms of waist circumference (MD: -1.34 cm, 95%CI: -2.75 to 0.07; Z=1.86, P=0.06) compared with the placebo group. The GRADE profiles indicated very low-quality evidence for body weight change and low-quality evidence for BMI change. SGLT2 inhibitors were generally safe and well tolerated.SGLT2 inhibitors could be used in selected adults with overweight and obesity but not diabetes if they are at low risk of genital infection and urinary infection. Further studies are warranted to confirm the efficacy and safety of SGLT2 inhibitors in adults with overweight or obesity but not diabetes for long-term weight management.[https://www.crd.york.ac.uk/prospero/#loginpage], identifier [PROSPERO, CRD42021252931]." @default.
• W3195903332 created "2021-08-30" @default.
• W3195903332 creator A5009933871 @default.
• W3195903332 creator A5035585872 @default.
• W3195903332 creator A5036421899 @default.
• W3195903332 creator A5050128295 @default.
• W3195903332 creator A5066253638 @default.
• W3195903332 creator A5082089345 @default.
• W3195903332 creator A5091607881 @default.
• W3195903332 date "2021-08-16" @default.
• W3195903332 modified "2023-09-30" @default.
• W3195903332 title "Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis" @default.
• W3195903332 cites W1997018189 @default.
• W3195903332 cites W2024892781 @default.
• W3195903332 cites W2036504033 @default.
• W3195903332 cites W2039596275 @default.
• W3195903332 cites W2087008856 @default.
• W3195903332 cites W2093043874 @default.
• W3195903332 cites W2109366467 @default.
• W3195903332 cites W2113943669 @default.
• W3195903332 cites W2130570549 @default.
• W3195903332 cites W2146264128 @default.
• W3195903332 cites W2153839551 @default.
• W3195903332 cites W2157349316 @default.
• W3195903332 cites W2168450459 @default.
• W3195903332 cites W2169205464 @default.
• W3195903332 cites W2463888723 @default.
• W3195903332 cites W2514508198 @default.
• W3195903332 cites W2595578651 @default.
• W3195903332 cites W2602313931 @default.
• W3195903332 cites W2626446274 @default.
• W3195903332 cites W2754111433 @default.
• W3195903332 cites W2782148351 @default.
• W3195903332 cites W2792068126 @default.
• W3195903332 cites W2972934327 @default.
• W3195903332 cites W2984052090 @default.
• W3195903332 cites W2996866740 @default.
• W3195903332 cites W3021074130 @default.
• W3195903332 cites W3086572118 @default.
• W3195903332 cites W3086985336 @default.
• W3195903332 cites W3089153468 @default.
• W3195903332 cites W3093156849 @default.
• W3195903332 cites W3136294064 @default.
• W3195903332 cites W3138140517 @default.
• W3195903332 cites W3160736678 @default.
• W3195903332 doi "https://doi.org/10.3389/fendo.2021.706914" @default.
• W3195903332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8415407" @default.
• W3195903332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34484120" @default.
• W3195903332 hasPublicationYear "2021" @default.
• W3195903332 type Work @default.
• W3195903332 sameAs 3195903332 @default.
• W3195903332 citedByCount "20" @default.
• W3195903332 countsByYear W31959033322021 @default.
• W3195903332 countsByYear W31959033322022 @default.
• W3195903332 countsByYear W31959033322023 @default.
• W3195903332 crossrefType "journal-article" @default.
• W3195903332 hasAuthorship W3195903332A5009933871 @default.
• W3195903332 hasAuthorship W3195903332A5035585872 @default.
• W3195903332 hasAuthorship W3195903332A5036421899 @default.
• W3195903332 hasAuthorship W3195903332A5050128295 @default.
• W3195903332 hasAuthorship W3195903332A5066253638 @default.
• W3195903332 hasAuthorship W3195903332A5082089345 @default.
• W3195903332 hasAuthorship W3195903332A5091607881 @default.
• W3195903332 hasBestOaLocation W31959033321 @default.
• W3195903332 hasConcept C126322002 @default.
• W3195903332 hasConcept C134018914 @default.
• W3195903332 hasConcept C142724271 @default.
• W3195903332 hasConcept C168563851 @default.
• W3195903332 hasConcept C204787440 @default.
• W3195903332 hasConcept C27081682 @default.
• W3195903332 hasConcept C2777180221 @default.
• W3195903332 hasConcept C2780221984 @default.
• W3195903332 hasConcept C2780473172 @default.
• W3195903332 hasConcept C2780586474 @default.
• W3195903332 hasConcept C44249647 @default.
• W3195903332 hasConcept C511355011 @default.
• W3195903332 hasConcept C544821477 @default.
• W3195903332 hasConcept C555293320 @default.
• W3195903332 hasConcept C71924100 @default.
• W3195903332 hasConcept C82789193 @default.
• W3195903332 hasConcept C95190672 @default.
• W3195903332 hasConceptScore W3195903332C126322002 @default.
• W3195903332 hasConceptScore W3195903332C134018914 @default.
• W3195903332 hasConceptScore W3195903332C142724271 @default.
• W3195903332 hasConceptScore W3195903332C168563851 @default.
• W3195903332 hasConceptScore W3195903332C204787440 @default.
• W3195903332 hasConceptScore W3195903332C27081682 @default.
• W3195903332 hasConceptScore W3195903332C2777180221 @default.
• W3195903332 hasConceptScore W3195903332C2780221984 @default.
• W3195903332 hasConceptScore W3195903332C2780473172 @default.
• W3195903332 hasConceptScore W3195903332C2780586474 @default.
• W3195903332 hasConceptScore W3195903332C44249647 @default.
• W3195903332 hasConceptScore W3195903332C511355011 @default.
• W3195903332 hasConceptScore W3195903332C544821477 @default.
• W3195903332 hasConceptScore W3195903332C555293320 @default.
• W3195903332 hasConceptScore W3195903332C71924100 @default.
• W3195903332 hasConceptScore W3195903332C82789193 @default.
• W3195903332 hasConceptScore W3195903332C95190672 @default.
• W3195903332 hasLocation W31959033321 @default.
• W3195903332 hasLocation W31959033322 @default.

• next